Fibrocell Science Inc. (FCSC)

2.98
0.01 0.17
NASDAQ : Health Technology
Prev Close 2.98
Open 2.98
Day Low/High 2.98 / 2.99
52 Wk Low/High 1.45 / 3.28
Volume 973.00
Avg Volume 137.40K
Exchange NASDAQ
Shares Outstanding 9.76M
Market Cap 29.17M
EPS -1.40
P/E Ratio 8.51
Div & Yield N.A. (N.A)

Latest News

SHAREHOLDER ALERT: Monteverde & Associates PC Is Investigating The Following Transaction

SHAREHOLDER ALERT: Monteverde & Associates PC Is Investigating The Following Transaction

NEW YORK, Sept. 18, 2019 /PRNewswire/ -- Juan Monteverde , founder and managing partner at Monteverde & Associates PC, a national securities firm headquartered at the Empire State Building in New York City, is investigating: Mam Software Group, Inc.

Castle Creek Pharmaceutical Holdings Announces Agreement To Acquire Fibrocell

Castle Creek Pharmaceutical Holdings Announces Agreement To Acquire Fibrocell

Castle Creek will advance multiple late-stage clinical development programs targeting epidermolysis bullosa

Castle Creek Pharmaceutical Holdings To Acquire Fibrocell

Castle Creek Pharmaceutical Holdings To Acquire Fibrocell

- Total consideration of $63.3 million, including repayment of debt and other financial instruments - - Acquisition expected to close in the fourth quarter of 2019 - - Further strengthens Castle Creek Pharmaceuticals as a leader in dermatology - EXTON, Pa.

Fibrocell Reports Second Quarter 2019 Financial Results And Recent Operational Highlights

Fibrocell Reports Second Quarter 2019 Financial Results And Recent Operational Highlights

- Company to Host Conference Call and Webcast on Thursday, August 15 at 8:30 a.m.

These 2 Biotech Stocks Are No Longer 'Off the Radar'

These 2 Biotech Stocks Are No Longer 'Off the Radar'

Few parts of the market have more volatility than the small caps in this sector.

Small-Caps Are the Place to Be for Now

Small-Caps Are the Place to Be for Now

We are seeing a focus on finding smaller names that may offer interesting valuations and stories.

Fibrocell Reports Third Quarter 2017 Financial Results And Recent Highlights

Fibrocell Reports Third Quarter 2017 Financial Results And Recent Highlights

Company to Host Conference Call and Webcast Today at 8:30 a.m. EST

Fibrocell Reports Second Quarter 2017 Financial Results And Recent Highlights

Fibrocell Reports Second Quarter 2017 Financial Results And Recent Highlights

Company to Host Conference Call and Webcast Today at 8:30 a.m. EDT

Fibrocell Receives Rare Pediatric Disease Designation From FDA For FCX-013 For Treatment Of Localized Scleroderma

Gene Therapy Candidate under Control of RheoSwitch Therapeutic System® Technology is Potential First-in-Class Treatment for Chronic Disease with High Unmet Need